Disc Medicine, Inc.

Disc Medicine, Inc. (Nasdaq: GMTX) is a clinical-stage biopharmaceutical company focused on developing treatments for serious hematological diseases, including conditions involving disordered erythropoiesis and iron metabolism. The company entered the public markets in 2022 through a reverse merger with shell company Gemphire Therapeutics, Inc., effectively assuming the GMTX ticker on Nasdaq. The company filed an 8-K with the Securities and Exchange Commission on June 13, 2025, under accession number 0000950170-25-086352, disclosing a material corporate event. Disc Medicine operates in the clinical-stage biopharma and rare hematology sector. For full filing details, pipeline status, and ongoing corporate event tracking on GMTX, sign up for a SpacDesk account at spacdesk.com.